Creon (pancrelipase delayed-release) / AbbVie, Eisai 
Welcome,         Profile    Billing    Logout  
 23 Diseases   11 Trials   11 Trials   339 News 


123»
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    THE RECOMBINANT CILIATE LIPASE CILIP IS A HIGHLY EFFECTIVE NOVEL EPI DRUG AND SUPERIOR TO ESTABLISHED PANCREATIN BASED THERAPIES (Hall A) -  Mar 14, 2024 - Abstract #DDW2024DDW_7205;    
    CiLip provides the treating physician with an alternative to the established pancreatin products that is clearly superior to them in terms of purity, safety and specific activity. The lipase presented here opens up the possibility of increasing the lipolytic activity in pancreatin products, as well as treatment with pure lipase in cases where the use of protease is not desirable.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    Pseudo Bartter Syndrome in a Kenyan Infant With Genetically Confirmed Cystic Fibrosis: Case Report (San Diego Convention Center, Area G (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_4039;    
    The significance of the mutations associated with primary ciliary dyskinesia and Chediak Higashi syndrome in this child could not be ascertained due lack of functional testing. Global access to affordable CF treatment is needed.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    Journal:  Anti-Incretin Gut Features Induced by Feed Supplementation with Alpha-Amylase: Studies on EPI Pigs. (Pubmed Central) -  Nov 29, 2023   
    Orally administered amylase induces gut anti-incretin action, normalizing glucose homeostasis and reducing HOMA-IR as a long-term outcome, thus lowering the risk of diabetes type II development. Amylase has long-lasting anti-incretin effects, and one could consider the existence of a long-lasting gut memory for amylase, which decreases hyperinsulinemia and hyperglycemia for up to 16 h after the last exposure of the gut to amylase.
  • ||||||||||  Journal:  GluCl.CreON enables selective inhibition of molecularly defined pain circuits. (Pubmed Central) -  Nov 17, 2023   
    Collectively, we have generated a novel tool that can be used to selectively silence defined neuronal circuits in vitro and in vivo. We believe that this addition to the chemogenetic tool box will facilitate further understanding of pain circuits and guide future therapeutic development.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    Trial completion date, Trial primary completion date:  CREON: Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes (clinicaltrials.gov) -  Sep 6, 2023   
    P1,  N=10, Enrolling by invitation, 
    Active, not recruiting --> Completed Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Aug 2023 --> Aug 2024
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, Creon (pancrelipase delayed-release) / AbbVie, Eisai
    Pancreatic Elastase Deficiency in Gastrointestinal Strongyloidiasis (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3119;    
    He was treated with neomycin, rifaximin, and creon...The lamina propria contains abundant eosinophils (>100 per high-power field). Focally, within crypts there are parasitic organisms consistent with Strongyloides stercoralis.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    Coca-Cola and Creon Therapy for Esophageal Food Bolus Impaction and Bezoar (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_991;    
    In our experience, this method appears to be a safe, effective and inexpensive treatment, and should be considered an alternative therapy when endoscopy is unsuccessful prior to more aggressive interventions. Figure: A) Coronal section of chest CT showing distended esophagus with impacted food bolus (yellow arrow) B and C) Initial upper endoscopy with food bolus and bezoar impaction in the proximal and distal esophagus respectively D and E) Repeat endoscopy showing clearance of food bolus and bezoar post cocktail of creon and coca cola
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    A Not so Common Case of Recurrent Acute Pancreatitis and Its Implications (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_523;    
    Subsequent ERCP performed in next acute pancreatitis episode which showed what was a ansa loop rather than an ampullary lesion. Endoscopist proceeded to place a pancreatic duct stent which subsequently was successful in avoiding recurrent episodes of acute pancreatitis.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    The impact of modulators on faecal elastase in children with cystic fibrosis (Poster Area) -  May 9, 2023 - Abstract #ECFS2023ECFS_580;    
    However, improvement of clinical symptoms of malabsorption does not always correlate with biochemical analysis, which can make advice/dosing of pancreatic replacement therapy challenging. Data collection is ongoing, with further data becoming available.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    The effect quality of life on cystic fibrosis children patients in Gaza Strip (Poster Area) -  May 9, 2023 - Abstract #ECFS2023ECFS_469;    
    Approximately 47% of them were less than 9 years and 53% were more than 9 years. About 41.7% of the study population from Gaza, 25.0% from middle zone, 13.9% from Rafah, 11.1% from Khanyounis and 8.3% from North of Gaza.
  • ||||||||||  Trikafta (elexacaftor/tezacaftor/ivacaftor) / Vertex, Creon (pancrelipase delayed-release) / AbbVie, Eisai
    Theratyping  (Poster Area) -  May 9, 2023 - Abstract #ECFS2023ECFS_457;    
    We suggest that ETI should be approved for patients with this mutation. These reported cases support the idea that modulators can be tried for mutations that show in vitro activity, and continued for those with clinical response.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    WHAT IS THE SIGNIFICANCE OF A FAECAL ELASTASE-1 LEVEL BETWEEN 200-500MG/G? (South Hall A, Poster Hall - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_5146;    
    Although it is often believed patients with PEI will only display symptoms when pancreatic function has dropped to <10%, there is now a consensus that these patients may instead demonstrate a graded response to reduced exocrine function and so will benefit from having earlier testing and treatment. Indeed, our findings support this suggestion, with nearly
  • ||||||||||  Estring (estradiol) / Pfizer, Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Creon (pancrelipase delayed-release) / AbbVie, Eisai
    A CASE OF TRANSIENT EXOCRINE PANCREATIC DYSFUNCTION AFTER PFIZER-BIONTECH COVID-19 MRNA VACCINATION. (South Hall A, Poster Hall - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_5142;    
    The highly efficient drug formulation overcomes the limitations of pancreatin products by a constant high quality and activity, pH stability and purity. We present a case of transient exocrine pancreatic insufficiency (EPI) that occurred after administration of the Pfizer-BioNTechCOVID-19 mRNA vaccine (Comirnaty
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie
    Enrollment closed, Enrollment change:  PB-SAM: Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children (clinicaltrials.gov) -  Feb 24, 2023   
    P2/3,  N=400, Active, not recruiting, 
    We present a case of transient exocrine pancreatic insufficiency (EPI) that occurred after administration of the Pfizer-BioNTechCOVID-19 mRNA vaccine (Comirnaty Not yet recruiting --> Active, not recruiting | N=1200 --> 400
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie
    Trial completion date, Trial primary completion date:  CisCP: Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms (clinicaltrials.gov) -  Dec 8, 2022   
    P=N/A,  N=90, Recruiting, 
    This may impact their therapeutic efficacy and, therefore, may limit their interchangeability. Trial completion date: Aug 2022 --> Jun 2023 | Trial primary completion date: Aug 2022 --> Jun 2023
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie
    Pancreatitis Due to Novel Gene Mutation of Cystic Fibrosis Transmembrane Conductance Regulator Gene (Anaheim Convention Center, Hall A, Board # 150) -  Nov 10, 2022 - Abstract #AAPNCE2022AAP_NCE_2345;    
    Due to continued research, multiple genetic variants of the CFTR gene have been identified and their ability to cause a spectrum of disorder in relation to cystic fibrosis. Further research will need to be done to evaluate if the complex R74W;R1070W;D1270N mutation corresponds with other clinical presentations.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie
    Intersectional Genetics Tools Reveal Cell-Type Specific Transcriptional Networks of Co-Transmitting Dopaminergic and Glutamatergic Neurons (Grand Canyon 3-5) -  Oct 31, 2022 - Abstract #ACNP2022ACNP_250;    
    We identified major pathways related to mitochondrial function, reactive oxygen species, bioenergetics, and presynaptic vesicle trafficking and release in TH+/VGLUT2+ neurons of the midbrain, along with the identification of potential upstream regulators and modulators of Vglut2 expression. These candidates may be involved in various disease-related processes in the brain, including substance use disorders and Neurodegeneration.
  • ||||||||||  HSV Esophagitis With Hematemesis and Recalcitrant Food Bolus (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_1903;    
    Her past medical history includes refractory AML with HSCTs in 2007, 2010 and 2019 and GI graft-versus-host-disease (GVHD) on talazoparib and gemtuzumab...She was given IV foscarnet, acyclovir, pantoprazole and sucralfate...She continued HSV prophylaxis with valganciclovir and did not develop recurrent HSV-E despite ongoing immunosuppression...Age >50 is associated with reactivation higher risk and HSV reactivation in the setting of cancer is associated with decreased overall survival. Figure: Figure 1: Upper GI endoscopy image from week 1 showing hemorrhagic and ulcerated (arrows) esophageal mucosa.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie
    WHAT IS THE SIGNIFICANCE OF A FAECAL ELASTASE-1 LEVEL BETWEEN 200 – 500MG/G? (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2549;    
    Although it is often believed patients with PEI will only display symptoms when pancreatic function has dropped to < 10%, there is now a consensus that these patients may instead demonstrate a graded response to reduced exocrine function and so will benefit from having earlier testing and treatment [4]. Indeed, our findings support this suggestion, with nearly ¼ of patients with a FE-1 of between 200-500 showing a response following treatment with PERT.
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie, Eisai
    Trial initiation date:  CREON: Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes (clinicaltrials.gov) -  Jul 5, 2022   
    P1,  N=10, Enrolling by invitation, 
    Indeed, our findings support this suggestion, with nearly ¼ of patients with a FE-1 of between 200-500 showing a response following treatment with PERT. Initiation date: May 2022 --> Aug 2022
  • ||||||||||  Creon (pancrelipase delayed-release) / AbbVie
    Journal:  Impact of Pancreatic Enzymes on Enteral Fat and Nitrogen Absorption in Short Bowel Syndrome. (Pubmed Central) -  Jun 30, 2022   
    These results suggest that some patients with SBS may benefit from treatment with pancreatic enzymes. Further studies are needed to better evaluate the effect of pancreatic enzyme therapy on enteral absorption in subjects with SBS and to characterize factors that may predict a positive response.